With the implementation of the revised version of GMP2010 and the implementation of the Chinese Pharmacopoeia 2015, the State Food and Drug Administration has intensified inspections of the integrity of R&D on-site inspections and clinical trial data, and has also intensified the inspection of drug manufacturers. Under strict drug supervision and inspection, how should drug companies respond?
SinoFour focuses on the design and implementation of GMP projects in the pharmaceutical industry. With rich project experience in API, intermediates and BMS/EMS based on GAMP5 v-model, the core team has more than 10 years of GMP5 validation experience, and will provide the most professional validation consulting services for customers.
English
中文